E - Drug-resistant TB care and treatment, except clinical trials
Post-graduate course (PGC)
11:00 – 17:30
Session Room 11C

01. Update on clinical and programmatic management of MDR- and XDR-TB

Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose a significant threat to TB control and challenge clinicians and programme managers worldwide due to the complexities in diagnosis, treatment, and case management. This course presents cutting-edge strategies for clinical and programmatic management of MDR-TB for the front-line clinician, nurse, epidemiologist, laboratorian and programme manager, based on the newly updated WHO guidelines. It will use case-based presentations to illustrate internationally recommended practices to address the challenges of MDR-TB diagnosis, treatment and care.

How the post-graduate course is related to the conference:
The course is directly related to the theme of the 47th Union World Conference on Lung Health because addressing the problem of MDR- and XDR-TB will be one of the main challenges as we move forward towards TB control and elimination beyond 2016. Appropriate prevention and management of MDR/XDR TB will be the key for the future of TB control.

Objectives:
Through a series of illustrative case presentations, to:
1) Present the principles of MDR-TB prevention, diagnosis, treatment and care.
2) Update on recent advances in rapid diagnosis of drug resistance and to discuss how these advances may be applied in the clinical setting
3) Discuss evidence-based management of and controversial issues in the treatment of MDR/XDR-TB and MDR-TB/HIV and other special situations
4) Present cutting edge strategies for the treatment and management of MDR/XDR-TB including new drugs and new drug regimens for the treatment of active disease
5) Introduce practical management of MDR-TB in resource-limited settings, especially with a high burden of TB-HIV co-infection, including ambulatory and community-based initiatives
6) Discuss prevention strategies for MDR/XDR-TB
7) Present the most effective strategies for proper management of adverse reactions to second-line anti-TB drugs
8) Update on the ethics principles to guide the prevention, diagnosis, treatment and care of TB

Coordinator: Sundari Mase, United States of America
Coordinator: Ignacio Monedero, Spain

Updated guidelines on molecular tests for the diagnosis of DR-TB
Christopher Gilpin, Switzerland

Use of new anti-TB drugs for treatment of MDR-TB
Malik Parmar, India

Designing a treatment regimen for MDR-TB according to new WHO guidelines: presentation of a clinical case
Jose Caminero Luna, Spain

Treatment regimen for special MDR-TB situations in which new drugs are used: presentation of a clinical case
Barbara Seaworth, United States of America

Treatment of MDR-TB: HIV co-infection, pregnancy
Jennifer Furin, United States of America

Treatment of MDR-TB: Childhood TB
Hendrik Simon Schaaf, South Africa
Scientific Programme

**Surgery in management of MDR-TB**  
Andrei Mariandyshev, Russian Federation

**Management of adverse drug reactions: presentation of a clinical case**  
Michael Rich, United States of America

**Patient-centred care to enable treatment adherence to new WHO recommendations**  
Ernesto Jaramillo, Switzerland

**Presentation of clinical cases**  
Ignacio Monedero, Spain

**Panel: Questions and final remarks**